Title: Trump’s Executive Order: A New Era in Psychedelic Drug Therapies? In an unexpected move, President Donald Trump signed an executive order aimed at accelerating research into psychedelic-based therapies, particularly drugs like ibogaine, for conditions such as PTSD, depression and addiction. The announcement was made on Saturday with Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz, top health officials and podcaster Joe Rogan in attendance at the White House. The president’s decision to sign this executive order comes after private lobbying from individuals like Joe Rogan who argued that experimental treatments have shown life-changing potential for those suffering from severe mental illnesses, including veterans with PTSD. Trump indicated that he was swayed by these arguments and decided to take action. Ibogaine, one of the drugs mentioned in the executive order, is currently classified as a schedule 1 controlled substance due to its high potential for abuse according to the U.S Drug Enforcement Agency (DEA). However, there have been limited studies on ibogaine’s effects on depression, PTSD, anxiety and traumatic brain injury with most evidence coming from animal studies and small human trials. While these studies are important components of research, they often do not translate well to humans due to differences in physiology and psychology between species. Despite the limited data available, there is some evidence suggesting that ibogaine carries serious safety risks, particularly a dangerous irregular heartbeat known as arrhythmia. This raises concerns about the potential implications of this executive order on public health if these therapies are approved for widespread use without sufficient research and testing. The historical context behind this decision includes previous attempts by other countries like Switzerland to legalize certain psychedelic drugs for therapeutic purposes, albeit with mixed results. In light of these past experiences, it remains uncertain how effective Trump’s executive order will be in accelerating the approval process and providing new treatment options for veterans suffering from severe mental health issues. In conclusion, while President Trump’s decision to sign an executive order aimed at accelerating research into psychedelic-based therapies is commendable, it raises several concerns about public safety and efficacy of these treatments without adequate testing and research. It will be interesting to see how this unfolds in the coming months as more information becomes available regarding the potential benefits and risks associated with these drugs.
Source: [Original Article](https://abcnews.com/Health/trump-signs-executive-order-accelerating-research-psychedelic-drug/story?id=132171927)
#trump
Check out my AI projects on Hugging Face, join our community on Discord, and explore my services at GhostAI!
